Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor.
Je Hyung ParkHyun Yul KimYoun Joo JungDong Il KimJee Yeon KimHyun-June PaikPublished in: Annals of surgical treatment and research (2019)
Patients with moderate- to high-grade tumors or CEA ≥ 5 ng/mL are required a double-check to determine the molecular subtype of breast cancer.